Enanta Pharmaceuticals | ENTA - Operating Profit


Enanta Pharmaceuticals reported $-23.54M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -25.73M 2.91M Sep/2024
Incyte USD 383.88M 47.43M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Merck USD 6.24B 318M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025